# Xiidra (lifitegrast) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/lifitegrast

> The FDA approved Xiidra (lifitegrast), sponsored by Bausch & Lomb Corp (BLCO), on July 11, 2016.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Xiidra (lifitegrast) |
| Codes |  |
| Sponsor | Bausch & Lomb Corp (BLCO) https://sec-api.dev/companies/blco/catalysts |
| Indications | [Dry Eye Disease](https://sec-api.dev/indications/dry-eye-disease) |
| Modality |  |
| FDA designations | priority review |

## Timeline

### July 11, 2016: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208073 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20160711, review_priority PRIORITY; sponsor_name BAUSCH AND LOMB INC; product XIIDRA (LIFITEGRAST)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208073%22

### May 28, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Dry Eye Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07128628 (A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-05-28 (ACTUAL); Lead Sponsor Bausch & Lomb Incorporated." https://clinicaltrials.gov/study/NCT07128628

## Same indication

- [ABBV-444](https://sec-api.dev/pdufa/abbv-444) (ABBV)
- [Bl1107 low dose](https://sec-api.dev/pdufa/bl1107) (BLCO)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/lifitegrast.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Xiidra (lifitegrast) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/lifitegrast

```bibtex
@misc{secapidev_pdufa_lifitegrast_20261116,
  title        = {Xiidra (lifitegrast) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/lifitegrast}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_lifitegrast_20261116","title":"Xiidra (lifitegrast) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/lifitegrast","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
